How genomic tests guide treatment for early breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how genomic tests (which analyze your tumor's genes) are used in routine care for early-stage breast cancer that is hormone-sensitive. It may help doctors understand who really needs chemotherapy in addition to hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have early-stage breast cancer that is hormone receptor positive (HR+) and HER2 negative.
- You have had surgery to remove your breast cancer and your lymph node status is known (no more than 1 lymph node with cancer cells that are not just isolated cells).
- Your doctor considers you at 'intermediate' risk of the cancer returning — not low risk and not high risk.
- You have had a genomic test (like Oncotype DX, MammaPrint, or similar) done on your tumor.
- You have not had breast cancer before, have no metastatic disease, and do not have other health problems that would prevent adjuvant therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
This trial tests whether some people with early-stage, hormone-positive breast cancer can safely skip chemotherapy and instead receive a targeted pill (ribociclib) with hormone therapy. A special blood test looks for tiny pieces of tumor DNA to help guide treatment decisions.
This study uses genetic testing of your tumor to find specific mutations and match you with targeted therapies, aiming to improve outcomes for advanced cancers with poor prognosis. If you have pancreatic, liver, or triple negative breast cancer and are starting treatment, this trial may help you access personalized treatment options.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.